Tuberculosis treatment outcome in the european union and european economic area: An analysis of surveillance data from 2002‒2011

Eurosurveillance

Volumn 20, Issue 49, 2015, Pages 1-10

  Karo, Basel ^a,b   Hauer, B ^a   Hollo, V ^c   Van der Werf, M J ^c   Fiebig, L ^a   Haas, W ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b PhD Programme Epidemiology   (Germany)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DISEASE SURVEILLANCE; DRUG SENSITIVITY; ECONOMIC ASPECT; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; AGED; CHILD; COHORT ANALYSIS; EUROPE; EUROPEAN UNION; FOLLOW UP; HEALTH SURVEY; INFANT; NEWBORN; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EUROPE; EUROPEAN UNION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84974822847     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2015.20.49.30087     Document Type: Article

References (34)

1. World Health Organization (WHO). 44th World Health Assembly, Resolutions and Decisions. Resolution WHA44.8. Geneva: WHO; 1991. Available from: http://www.who.int/tb/publications/tbresolution_wha44_8_1991.pdf?ua=1
2. Stop TB Partnership and World Health Organization. Global Plan to Stop TB 2006-2015: Actions for Life-Towards a world free of tuberculosis. WHO/HTM/STB/2006.35. Geneva: WHO; 2006. http://www.stoptb.org/assets/documents/global/plan/globalplanfinal.pdf
3. Rieder HL, Watson JM, Raviglione MC, Forssbohm M, Migliori GB, Schwoebel V, et al. Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting on tuberculosis cases. Eur Respir J. 1996;9(5):1097-104. Available from: DOI: 10.1183/09031936.96.09051097 PMID: 8793477
4. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J. 1998;12(2):505-10. Available from: DOI: 10.1183/09031936.98.12020505 PMID: 9727811
5. European Centre for Disease Prevention and Control (ECDC). A Framework Action Plan to fight Tuberculosis in the EU. Stockholm: ECDC; 2008. Available from: http://ecdc.europa.eu/en/publications/Publications/0803_SPR_TB_Action_plan.pdf
6. European Centre for Disease Prevention and Control/WHO Regional Office for Europe (ECDC/WHO EURO). Tuberculosis surveillance and monitoring in Europe 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf
7. Falzon D, Scholten J, Infuso A. Tuberculosis outcome monitoring--is it time to update European recommendations?Euro Surveill. 2006;11(3):20-5. PMID: 16567878
8. Manissero D, Hollo V, Huitric E, Kodmon C, Amato-Gauci A. Analysis of tuberculosis treatment outcomes in the European Union and European Economic Area: efforts needed towards optimal case management and control. Euro Surveill. 2010;15(11). PMID: 20338143
9. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005;26(3):503-10. Available from: DOI: 10.1183/09031936.05.00103504 PMID: 16135735
10. Falzon D, Le Strat Y, Belghiti F, Infuso A, Euro TB. Correspondents. Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tuberc Lung Dis. 2005;9(11):1224-9. PMID: 16333929
11. van Hest R, Kodmon C, Verver S, Erkens CG, Straetemans M, Manissero D, et al. Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J. 2013;41(3):635-43. Available from: DOI: 10.1183/09031936.00030612 PMID: 22790913
12. Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2013. Atlanta: CDC; October 2014. Available from: http://www.cdc.gov/tb/statistics/reports/2013/pdf/report2013.pdf
13. Public Health Agency of Canada. Tuberculosis in Canada 2012-Pre-Release. Ottawa (Canada): Minister of Public Works and Government Services Canada; 2014. Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tbcan13pre/assets/pdf/tbcan13pre-eng.pdf
14. Connolly C, Davies GR, Wilkinson D. Who fails to complete tuberculosis treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa. Int J Tuberc Lung Dis. 1999;3(12):1081-7. PMID: 10599011
15. Valin N, Hejblum G, Borget I, Mallet HP, Antoun F, Che D, et al. Management and treatment outcomes of tuberculous patients, eastern Paris, France, 2004. Int J Tuberc Lung Dis. 2009;13(7):881-7. PMID: 19555539
16. Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001.Int J Tuberc Lung Dis. 2003;7(2):124-31. PMID: 12588012
17. Working Group on Completion of Tuberculosis Treatment in Spain, Cayla JA, Caminero JA, Rey R, Lara N, Valles X, Galdos-Tanguis H. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8(4):458-64. PMID: 15141739
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Selected Issue 2: A gender perspective on drug use and responding to drug problems. ISBN 92-9168-250-0. Lisbon: EMCDDA; 2006. Available from: http://www.drugs.ie/resourcesfiles/ResearchDocs/Europe/Research/2006/sel2006_2-en.pdf
19. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014;209(3) Suppl 3;S100-6. Available from: DOI: 10.1093/infdis/jiu147 PMID: 24966189
20. Lefebvre N, Falzon D. Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J. 2008;31(6):1256-60. Available from: DOI: 10.1183/09031936.00131107 PMID: 18515556
21. Bustamante-Montes LP, Escobar-Mesa A, Borja-Aburto VH, Gomez-Munoz A, Becerra-Posada F. Predictors of death from pulmonary tuberculosis: the case of Veracruz, Mexico.Int J Tuberc Lung Dis. 2000;4(3):208-15. PMID: 10751065
22. Hauer B, Brodhun B, Altmann D, Fiebig L, Loddenkemper R, Haas W. Tuberculosis in the elderly in Germany. Eur Respir J. 2011;38(2):467-70. Available from: DOI: 10.1183/09031936.00199910 PMID: 21804163
23. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis. 2001;33(7):1034-9. Available from: DOI: 10.1086/322671 PMID: 11528577
24. Packham S. Tuberculosis in the elderly.Gerontology. 2001;47(4):175-9. Available from: DOI: 10.1159/000052794 PMID: 11408720
25. Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med. 2003;19(1):121-38. Available from: DOI: 10.1016/S0749-0690(02)00057-5 PMID: 12735118
26. Naalsund A, Heldal E, Johansen B, Kongerud J, Boe J. Deaths from pulmonary tuberculosis in a low-incidence country. J Intern Med. 1994;236(2):137-42. Available from: DOI: 10.1111/j.1365-2796.1994.tb01275.x PMID: 8046312
27. Rieder HL, Kelly GD, Bloch AB, Cauthen GM, Snider DE. Tuberculosis diagnosed at death in the United States. Chest. 1991;100(3):678-81. Available from: DOI: 10.1378/chest.100.3.678 PMID: 1889256
28. World Health Organization (WHO). Framework towards tuberculosis elimination in low-incidence countries. WHO/HTM/TB/2014.13. Geneva: WHO; 2014. Available from: http://apps.who.int/iris/bitstream/10665/132231/1/9789241507707_eng.pdf?ua=1
29. Ohmori M, Wada M, Yoshiyama T, Uchimura K. (Factors related to early case detection of tuberculosis in health service facilities for the elderly).Kekkaku. 2003;78(6):435-42. PMID: 12872702
30. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283(19):2537-45. Available from: DOI: 10.1001/jama.283.19.2537 PMID: 10815117
31. Noeske J, Nguenko PN. Impact of resistance to antituberculosis drugs on treatment outcome using World Health Organization standard regimens.Trans R Soc Trop Med Hyg. 2002;96(4):429-33. Available from: DOI: 10.1016/S0035-9203(02)90383-4 PMID: 12497982
32. Conaty SJ, Dart S, Hayward AC, Lipman MC. Reasons for low reported treatment success in notified tuberculosis patients from a London hospital according to new outcome reporting. Commun Dis Public Health. 2004;7(1):73-6. PMID: 15137286
33. World Health Organization (WHO). Resolution WHA 61.17. Health of migrants. In: Sixty-first World Health Assembly, Geneva, 19-24 May 2008. Resolutions and decisions, annexes. Geneva: WHO; 2008:2 (document WHA61/2008/REC/1). Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_REC1-en.pdf
34. Fernandes A, Miguel JP. Health and migration in European Union: better health for all in an inclusive society. 291173/09. Lisboa. Instituto Nacional de Saude Doutor Ricardo Jorge 2009. Available from: http://www.insa.pt/sites/INSA/Portugues/Publicacoes/Outros/Documents/Epidemiologia/HealthMigrationEU2.pdf